Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex H Chang

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Nature Communications|September 9, 2022
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignanciesYongxian Hu, Jingjing Li, Fang Ni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I TrialJing Pan, Yue Tan, Guoling Wang, et al.
The Lancet. Oncology|October 20, 2023
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 studyJing Pan, Kaiting Tang, Yuechen Luo, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myelomaChunxiang Jin, Rongrong Chen, Shan Fu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 5, 2020
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell LeukemiaXue Li, Xin Guo, Yuqing Zhu, et al.
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trialDian Zhou, Qian Sun, Jieyun Xia, et al.
Blood|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary diseaseDian Zhou, Yuekun Qi, Sha Ma, et al.
Journal of Advanced Research|February 13, 2025
Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up resultTingting Yang, Yetian Dong, Jimin Shi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2024
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trialLiping Zhao, Chuo Li, Shiyu Zuo, et al.
British Journal of Haematology|May 16, 2023
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre studyLinghui Zhou, Weijun Fu, Shenghao Wu, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Nature Communications|September 9, 2022
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignanciesYongxian Hu, Jingjing Li, Fang Ni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I TrialJing Pan, Yue Tan, Guoling Wang, et al.
The Lancet. Oncology|October 20, 2023
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 studyJing Pan, Kaiting Tang, Yuechen Luo, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myelomaChunxiang Jin, Rongrong Chen, Shan Fu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 5, 2020
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell LeukemiaXue Li, Xin Guo, Yuqing Zhu, et al.
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trialDian Zhou, Qian Sun, Jieyun Xia, et al.
Blood|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary diseaseDian Zhou, Yuekun Qi, Sha Ma, et al.
Journal of Advanced Research|February 13, 2025
Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up resultTingting Yang, Yetian Dong, Jimin Shi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2024
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trialLiping Zhao, Chuo Li, Shiyu Zuo, et al.
British Journal of Haematology|May 16, 2023
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre studyLinghui Zhou, Weijun Fu, Shenghao Wu, et al.
Pageof 8